Pharma & Bio
Technology
Cellbion Co., Ltd.’s ‘Pocubotide’ Clinical Trial: Why Market Sentiment Has Shifted
(Graphic: ChatGPT)
#Cellbion Co., Ltd.’s prostate cancer radiopharmaceutical candidate “Pocubotide Satetrasetate” (Lu-177-DGUL) is once again drawing attention for its existing clinical results. T…
- 2026-11-12 08:02:02
- Minji Son
Technology
Will SK BIOPHARMACEUTICALS’ Opakalim Clinical Trial Delay Be Prolonged? U.S.-Based Biohaven Says “We Are Preparing the Data”
SK BIOPHARMACEUTICALS(326030)Attention is focused on when the U.S. Food and Drug Administration (FDA) will lift its partial clinical hold on “Opakalim (BHV-7000),” a new epilepsy drug that SK Biopharm…
- 2026-11-12 08:02:01
- KIM SUNG-JIN
Technology
Earnings Soared, but the Outlook Remains Uncertain… Why i-SENS, Inc.’s Stock Price Plummeted
i-SENS, Inc.(099190)was unable to avoid a sharp drop in its stock price despite achieving record quarterly revenue in its continuous glucose monitoring (CGM) business. This is because, while its earni…
- 2026-11-12 07:06:02
- NA EUN-KYUNG
Business·Industry
Will K-Pihaja’s Subcutaneous Injection Conversion Technology Be Hindered by U.S. Drug Price Cuts? … The Outlook
Kim Jinsoo Alteogen Inc.(196170) Huons Global Co., Ltd.(084110), , and Huons Co., Ltd. Celltrion is actively utilizing SC formulation conversion technology, including by developing SC-formulated drugs…
- 2026-11-12 07:01:03
- Kim Jinsoo
Technology
Samil Pharm Hits Daily Upper Limit...Voronoi Jumps 15% [K-bio Pulse]
Shares of Samik Pharmaceutical, JW Shinyak, and Voronoi rose sharply on November 10 as the KOSPI and KOSDAQ both rebounded by more than 4%, drawing buying interest in small- and mid-cap pharmaceutical…
- 2026-11-12 06:02:03
- Kim Seung-kwon
Technology
SAMIK PHARM. Co., LTD. Listed on the Main Board, Voronoi, Inc. Up 15%… Biotech Sector Rides the Wave of Stock Market Rebound [Bio Spotlight]
On the 10th, stock prices for #SAMIK PHARM. Co., LTD., JW SHINYAK CORPORATION(067290), and Voronoi, Inc.(310210)surged in the domestic pharmaceutical and biotech market. As both the KOSPI and KOSDAQ r…
- 2026-11-12 06:02:02
- Kim Seung-kwon
Lifestyle
Vaxcell-bio Soars; Seegene, Alteogen Plunge [K-bio pulse]
Vaxcell-bio attracted strong investor interest after reporting preclinical results showing that its experimental chimeric antigen receptor T-cell (CAR-T) therapy demonstrated antitumor activity in sol…
- 2026-11-11 07:11:04
- Kim Jinsoo
Lifestyle
“The Era of Delayed Diagnosis Is Over… Dry Age-Related Macular Degeneration Affecting 200 Million People Ushering in a ‘Vision Restoration’ Revolution” [Expert Insight]
A paradigm shift in the treatment of dry age-related macular degeneration (AMD), which affects approximately 200 million people worldwide, is on the horizon. While existing treatments have been limite…
- 2026-11-11 07:11:03
- YU JIN-HEE
Lifestyle
Vaxcell-Bio Therapeutics’ CAR-T Achieves Complete Remission in Solid Tumors… Alteogen Inc. and Seegene Inc. Share Prices Fall [Bio Spotlight]
Vaxcell-Bio Therapeutics(323990)has attracted significant attention from investors after preclinical trials of its chimeric antigen receptor (CAR) T-cell therapy, currently under development, demonstr…
- 2026-11-11 07:11:02
- Kim Jinsoo
Technology
Shin Seung-jun, Executive Director at Hugel, Inc.: “Evidence Is Ultimately the Key to Persuading Medical Professionals; We Are Expanding Beyond Toxins to Fillers and Collagen”
“We do not make baseless claims, and even when evidence exists, we do not overinterpret it.”Hugel, Inc.(145020)Centered on its Medical Business Division, the company is focusing its efforts on academi…
- 2026-11-11 07:01:02
- Kim Seung-kwon
PHARM EDAILY
Shorts